Announcement • Jun 26
CalciMedica, Inc. announced that it expects to receive $15.000366 million in funding
CalciMedica, Inc. announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors for the private placement to issue 18,673,429 units at an issue price of $0.8033 for each unit or $0.8032 for each unit including a pre-funded warrant sold in lieu of common stock), for gross proceeds of $15,000,365.5157 on June 23, 2026. Each unit that is being issued at $0.8033 consists of One share of Common Stock, One right to receive a Series A Warrant, One right to receive a Series B Warrant, and each unit that is being issued at $0.8032 consists of One Pre-Funded Warrant to purchase one share of Common Stock One right to receive a Series A Warrant, One right to receive a Series B Warrant. The issuance of warrants are subject to Stockholder Approval. Each Pre-Funded Warrant will have an exercise price of $0.0001 per Pre-Funded Warrant Share, will be immediately exercisable on the date of issuance and will not expire. The Series A Warrants shall have an exercise price equal to $0.8033 per Warrant Share, will be exercisable immediately upon issuance and will expire on the earlier of (i) 18 months after the closing date of the Private Placement The Series B Warrants shall have an exercise price equal to $1.00 per Warrant Share, will be exercisable immediately upon issuance and will expire five years from the closing date of the Private Placement. The Series B Warrants will be issued upon receipt of Stockholder Approval. The transaction includes participation from Rachel Leheny, Ph.D., the Company’s Chief Executive Officer, a member of the board of directors of the Company (the “Board”) and a beneficial owner of more than 5% of the Company’s common stock, Eric Roberts, the Company’s Chief Business Officer, a member of the Board and a beneficial owner of more than 5% of the Company’s common stock, Sudarshan Hebbar, M.D., the Company’s Chief Medical Officer, Robert Wilson, a member of the Board, Sanderling Venture Partners VI Co-Investment Fund, L.P., a beneficial owner of more than 5% of the Company’s common stock and an affiliate of Fred Middleton, a member of the Board, Alafi Capital Company, LLC, a beneficial owner of more than 5% of the Company’s common stock, and Bering Partners II, L.P., a beneficial owner of more than 5% of the Company’s common stock for 6,908,996 Units. The closing of the Private Placement is expected to occur on or about June 25, 2026, subject to the satisfaction of customary closing conditions. The Private Placement is being conducted in accordance with applicable rules of The Nasdaq Stock Market LLC.
